Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

Read the full article here

Related Articles